NCT04172441View on ClinicalTrials.gov

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

February 17, 2022

Study Completion Date

March 7, 2022

Conditions
Congenital Hyperinsulinism
Interventions
DRUG

dasiglucagon

Glucagon analogue

DRUG

Placebo

Placebo for dasiglucagon

Trial Locations (6)

19104

Children's Hospital of Philadelphia, Philadelphia

39120

University Hospital, Magdeburg, Magdeburg

40225

University Children's Hospital, Düsseldorf

76104

Cook Children's Medical Center, Fort Worth

9765422

Hadassah Medical Center, Jerusalem

M13 9WL

Manchester University NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY

NCT04172441 - Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | Biotech Hunter | Biotech Hunter